Behavioural and neurophysiological effects of cannabidiol in children with autism

Nina Parella; Peter Enticott; Aron Hill; Sarah J. Catchlove; Luke A Downey; Talitha C. Ford

doi:10.1016/j.nsa.2023.102870

Behavioural and neurophysiological effects of cannabidiol in children with autism

Nina Parella
, Peter Enticott
, Aron Hill
, Sarah J. Catchlove
, Luke A Downey
, Talitha C. Ford

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Aims: To this end, we are conducting a randomised controlled trial that examines the effects of a weight-based dosing of a full-spectrum CBD oil on social communication, behavioural, and neurophysiological outcomes in autistic children.
Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).

Original language	English
Article number	102870
Number of pages	1
Journal	Neuroscience Applied
Volume	2
Issue number	Supplement 2
DOIs	https://doi.org/10.1016/j.nsa.2023.102870
Publication status	Published - 2023
Event	Congress of the European-College-of-Neuropsychopharmacology (ECNP) 2023 - Barcelona, Spain Duration: 7 Oct 2023 → 10 Oct 2023 Conference number: 36th https://www.sciencedirect.com/journal/neuroscience-applied/vol/2/suppl/S2 (Published Abstracts) https://www.ecnp.eu/Congress2023/ECNPcongress

Access to Document

10.1016/j.nsa.2023.102870Licence: CC BY-NC-ND

Cite this

@article{7d1f322818584e7b97a2bde591ed7cac,

title = "Behavioural and neurophysiological effects of cannabidiol in children with autism",

abstract = "Aims: To this end, we are conducting a randomised controlled trial that examines the effects of a weight-based dosing of a full-spectrum CBD oil on social communication, behavioural, and neurophysiological outcomes in autistic children. Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).",

author = "Nina Parella and Peter Enticott and Aron Hill and Catchlove, \{Sarah J.\} and Downey, \{Luke A\} and Ford, \{Talitha C.\}",

year = "2023",

doi = "10.1016/j.nsa.2023.102870",

language = "English",

volume = "2",

journal = "Neuroscience Applied",

issn = "2772-4085",

publisher = "Elsevier",

number = "Supplement 2",

note = "Congress of the European-College-of-Neuropsychopharmacology (ECNP) 2023, ECNP 2023 ; Conference date: 07-10-2023 Through 10-10-2023",

url = "https://www.sciencedirect.com/journal/neuroscience-applied/vol/2/suppl/S2, https://www.ecnp.eu/Congress2023/ECNPcongress",

}

TY - JOUR

T1 - Behavioural and neurophysiological effects of cannabidiol in children with autism

AU - Parella, Nina

AU - Enticott, Peter

AU - Hill, Aron

AU - Catchlove, Sarah J.

AU - Downey, Luke A

AU - Ford, Talitha C.

N1 - Conference code: 36th

PY - 2023

Y1 - 2023

N2 - Aims: To this end, we are conducting a randomised controlled trial that examines the effects of a weight-based dosing of a full-spectrum CBD oil on social communication, behavioural, and neurophysiological outcomes in autistic children. Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).

AB - Aims: To this end, we are conducting a randomised controlled trial that examines the effects of a weight-based dosing of a full-spectrum CBD oil on social communication, behavioural, and neurophysiological outcomes in autistic children. Methods: A total of 34 autistic children (determined by a priori power analysis), aged 5 to 12 years, are enrolled in this 12-week randomised, double-blind, placebo-controlled, cross-over, Phase I/II clinical trial. Participants are diagnosed with autism spectrum disorder in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Participants are randomised to receive either weight-based dosing of 10 mg/kg/day of Medigrowth CBD100, or placebo, for the first phase, followed by an 8-week washout before commencing the second 12-week treatment phase (cross-over).

U2 - 10.1016/j.nsa.2023.102870

DO - 10.1016/j.nsa.2023.102870

M3 - Meeting Abstract

SN - 2772-4085

VL - 2

JO - Neuroscience Applied

JF - Neuroscience Applied

IS - Supplement 2

M1 - 102870

T2 - Congress of the European-College-of-Neuropsychopharmacology (ECNP) 2023

Y2 - 7 October 2023 through 10 October 2023

ER -